Kamada

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: -

Employees: 378

Market Cap: $326M

Website

Introduction: Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

Clinical Trials

Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

Phase 1

Completed

Conditions: Pneumonia, Viral
Covid19

Interventions: Biological: Kamada Anti-SARS-CoV-2

First Posted Date: 2020-09-16

Last Posted Date: 2021-01-05

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 12

Registration Number: NCT04550325

Locations: 🇮🇱
Wolfson Medical Center, Holon, Israel
🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱
Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel

and more 1 locations

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Phase 3

Recruiting

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: Placebo
Drug: Alpha 1-Antitrypsin

First Posted Date: 2019-12-18

Last Posted Date: 2025-01-17

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 220

Registration Number: NCT04204252

Locations: 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
🇧🇪
University Hospital (UZ) Leuven, Leuven, Belgium

and more 6 locations

Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

Phase 3

Completed

Conditions: Rabies

Interventions: Drug: KamRAB - HRIG

First Posted Date: 2016-09-23

Last Posted Date: 2021-09-05

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 30

Registration Number: NCT02912845

Locations: 🇺🇸
ACH, Little Rock, Arkansas, United States

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Phase 2

Completed

Conditions: Transplantation, Lung Rejection

Interventions: Drug: GLASSIA® and Institution standard of care (SOC)

First Posted Date: 2015-11-25

Last Posted Date: 2021-09-01

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 30

Registration Number: NCT02614872

Locations: 🇮🇱
Pulmonary Institute - Rabin Medical Center, Petach Tikva, Israel

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Phase 2

Completed

Conditions: Rabies

Interventions: Drug: Active rabies vaccine (US-FDA approved)

First Posted Date: 2014-01-20

Last Posted Date: 2021-09-29

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 118

Registration Number: NCT02040090

Locations: 🇺🇸
Prism Research Inc, Saint Paul, Minnesota, United States

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

Phase 2

Completed

Conditions: New Onset Type-1 Diabetes

Interventions: Biological: Alpha-1 Antitrypsin
Other: Placebo

First Posted Date: 2013-12-09

Last Posted Date: 2018-10-11

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 70

Registration Number: NCT02005848

Locations: 🇮🇱
Assaf Harofe Medical Center, Zerifin, Israel
🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱
Schneider Children's Medical Center, Pethach Tikva, Israel

and more 1 locations

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

Phase 2

Completed

Conditions: Alpha-1 Antitrypsin Deficiency

Interventions: Drug: Kamada-AAT for Inhalation, 80mg
Drug: Placebo
Drug: Kamada-AAT for Inhalation, 160mg

First Posted Date: 2013-12-05

Last Posted Date: 2020-01-18

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 36

Registration Number: NCT02001688

Locations: 🇺🇸
The University of Texas Health Science Center at Tyler Center for Clinical Research, Tyler, Texas, United States
🇺🇸
University of Florida, Pulmonary, Critical Care & Sleep Medicine, Gainesville, Florida, United States

Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Alpha-1 Antitrypsin 60mg (AAT, Glassia®)
Drug: Alpha-1 Antitrypsin 80mg (AAT, Glassia®)
Drug: Alpha-1 Antitrypsin 40mg (AAT, Glassia®)

First Posted Date: 2011-02-25

Last Posted Date: 2016-06-09

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 24

Registration Number: NCT01304537

Locations: 🇮🇱
Assaf Haroffeh Medical Center, Zerifin, Israel
🇮🇱
Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes at Schneider Children's Medical Center of Israel, Petach Tikva 49202, Israel

International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

Phase 2

Completed

Conditions: Emphysema

Interventions: Biological: Kamada AAT for inhalation
Other: Placebo

First Posted Date: 2010-10-08

Last Posted Date: 2019-11-29

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 168

Registration Number: NCT01217671

Locations: 🇨🇦
Seymour Health Centre, Vancouver, Canada
🇩🇰
Gentofte Hospital, Hellerup, Denmark
🇩🇪
Universitatsklinikum Gieben und Marburg, Marburg, Germany

and more 9 locations

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

First Posted Date: 2007-07-12

Last Posted Date: 2016-06-09

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 21

Registration Number: NCT00499837

Locations: 🇮🇱
Hadassah Hebrew University, Medical Center, Jerusalem, Israel

Home Terms & Conditions Privacy Policy